Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer

Publisher： Karger

E-ISSN： 2296-5262|40|1-2|21-26

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.40, Iss.1-2, 2017-01, pp. : 21-26

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Open-Label Safety Study of First-Line Bevacizumab in Combination with Standard Chemotherapy in Chinese Patients with Metastatic Colorectal Cancer Treated in an Expanded Access Program in Taiwan

By  

Oncology, Vol. 84, Iss. 5, 2013-03 ,pp. : 299-304

Karger

Access to resources Recommend Favorite

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

By  

Oncology, Vol. 92, Iss. 4, 2017-02 ,pp. : 205-212

Karger

Access to resources Recommend Favorite

Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 67-71

Karger

Access to resources Recommend Favorite

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)

By Lawrence Donna   Maschio Michael   Leahy Kevin J.   Yunger Simon   Easaw Jacob C.   Weinstein Milton C.  

Journal of Medical Economics, Vol. 16, Iss. 12, 2013-12 ,pp. : 1387-1398

Informa Healthcare

Access to resources Recommend Favorite

Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer

By  

Oncology, Vol. 77, Iss. 2, 2009-07 ,pp. : 113-119

Karger

Access to resources Recommend Favorite